Comparatire Study on Lansoprazole and Mosapride in Treatment of Patients with Bile—reflux Gastritis
Abstract
Objective:To compare the efficacy of Lansoprazole and Mosapride in treatment of patients With bile-reflux gastritis.Methods:Patients,confirmed with bile reflux gastritis,were enolled in the study.Patients were randomly assigned intocontrolgroup(n=50),Lansoprazolegroup(n=50,20mgdaily),Mosapride group(n=50,1.0g three times daily)andLansoprazole combinedMosapridewith group(combination group,n=50)and treated for 8 weeks.Dyspeptic symptoms of abdominal pain,bloating,heartburn and bitter taste were observed.Results:The dyspeptic symptoms were relieved in three groups after treatment.Conclusion:Lansoprazole combined with Mosapride might be effective in the treatment of patients with bile reflux gastritis.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 5,020 participants or records.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.